Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold ...
Background Increasing reports of life-threatening complications in young children exposed to skin-lightening products present a significant public health concern, yet this issue remains ...
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp, Bloomberg News reported on Wednesday, citing people familiar with the matter. The ...
MADISON - Exact Sciences Corp. (NASDAQ:EXAS) announced pivotal clinical validation results from its ALTUS study showing that its Oncoguard Liver blood test significantly outperforms ultrasound in ...
India have lost three matches and drawn one in the 2025-2027 WTC cycle so far India's current points percentage stands at just over 54, placing the team 4th in the standings India must win at least 8 ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...
(RTTNews) - Exact Sciences Corp. (EXAS), Friday announced the landmark clinical results from its ALTUS study, showing that the Oncoguard Liver blood test significantly outperforms ultrasound in ...
Abbott Laboratories is nearing a potential acquisition of cancer screening company Exact Sciences Corp., people familiar with the matter said, in what could be the biggest deal of the year in the ...
ALTUS study is the largest prospective trial of a blood test for liver cancer surveillance in the United States, reflecting the racial and ethnic diversity of high-risk groups MADISON, Wis., November ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ ...
Hosted on MSN
Madison's Exact Sciences' $23 billion sale is tied to its Cologuard cancer test. What to know
The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...
ALTUS study is the largest prospective trial of a blood test for liver cancer surveillance in the United States, reflecting the racial and ethnic diversity of high-risk groups Exact Sciences Corp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results